A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a 'pre-pandemic' influenza vaccine is underway. Investigators are evaluating whether imiquimod cream, commonly used to treat genital warts and certain skin cancers, can boost the body's immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years.